Europe's most valuable company has invested billions in Kalundborg on Denmark's coast - but it has many problems.

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

In a groundbreaking new study, Ozempic was found to be so effective at treating arthritis that people no longer needed ...

The company is expected to offer data on the higher dosing arms of 60, 80 and 100 milligrams at Obesity Week, which is organized by the Obesity Society and takes place Nov. 3-6 in San Antonio, Texas.

( NewsNation) — An active ingredient in some weight-loss drugs could help people suffering from osteoarthritis knee pain, a ...

With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

The trial was funded by Novo Nordisk, the drug company that makes semaglutide ... Related Weight-loss surgeries decline 25% ...